Wave Life Sciences LTD Form 4 insider transactions

Ra Capital Management, L.P. and 3 others reported changes in beneficial ownership of Wave Life Sciences Ltd. common stock on October 5, 2026.

Gregory L. Verdine, a Director of Wave Life Sciences Ltd., reported multiple transactions in common stock on October 5, 2026.

Aik Na Tan, a Director of Wave Life Sciences Ltd., reported multiple transactions in common stock on October 5, 2026.

Ken Takanashi, a Director of Wave Life Sciences Ltd., reported multiple transactions in common stock on October 5, 2026.

Mark Corrigan, a Director of Wave Life Sciences Ltd., reported multiple transactions in common stock on October 5, 2026.

Adrian Rawcliffe, a Director of Wave Life Sciences Ltd., reported multiple transactions in common stock on October 5, 2026.

Heidi L Wagner, a Director of Wave Life Sciences Ltd., reported multiple transactions in common stock on October 5, 2026.

Christian O Henry, a Director of Wave Life Sciences Ltd., reported multiple transactions in common stock on October 5, 2026.

Heidi L Wagner, a Director of Wave Life Sciences Ltd., sold 7,000 shares of common stock on August 11, 2026 for $6.01 per share.

Adrian Rawcliffe, a Director of Wave Life Sciences Ltd., sold 12,700 shares of common stock on August 12, 2026 for $5.29 per share.

Ken Takanashi, a Director of Wave Life Sciences Ltd., sold 3,864 shares of common stock on August 11, 2026 for $6.01 per share.

Aik Na Tan, a Director of Wave Life Sciences Ltd., sold 432 shares of common stock on August 11, 2026 for $6.01 per share.

RA Capital Management, a significant shareholder and board member, increased its beneficial ownership in Wave Life Sciences Ltd. through multiple open market purchases.

A Wave Life Sciences Ltd. executive exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged trading plan.

Wave Life Sciences CFO Kyle Moran reported significant equity awards, including restricted stock units and stock options, alongside a tax-related share sale.

Wave Life Sciences CEO Paul Bolno reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of shares.

A Wave Life Sciences executive reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of ordinary shares.

Wave Life Sciences CTO Chandra Vargeese reported acquisition of restricted share units and stock options, alongside a tax-related sale of ordinary shares.

Wave Life Sciences SVP Chris Francis exercised options and sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

GSK plc, a 10% owner and director, acquired 1.47 million ordinary shares of Wave Life Sciences Ltd. for $19 per share, increasing its indirect beneficial ownership to over 18.2 million shares.

Adrian Rawcliffe, a Director at Wave Life Sciences Ltd., exercised options and subsequently sold 42,000 ordinary shares under a pre-arranged trading plan.

Wave Life Sciences Director Heidi L. Wagner executed a planned sale of 14,000 ordinary shares following option exercises.

Wave Life Sciences Director Christian O. Henry executed a series of option exercises and subsequent sales of ordinary shares totaling 93,445 shares on December 8, 2025, under a Rule 10b5-1 trading plan.

A director at Wave Life Sciences Ltd. executed a series of option exercises and subsequent share sales totaling a significant amount of ordinary shares under a pre-arranged trading plan.

Wave Life Sciences Director Gregory L. Verdine sold 20,000 ordinary shares for approximately $270,000 through a pre-arranged 10b5-1 trading plan.

Wave Life Sciences SVP Chris Francis exercised stock options and sold 441,031 ordinary shares on December 8, 2025, under a pre-arranged 10b5-1 trading plan.

Wave Life Sciences Ltd. CFO Kyle Moran executed a series of option exercises and subsequent share sales totaling 260,036 shares under a pre-arranged 10b5-1 trading plan.

Wave Life Sciences Director Mark Corrigan sold 16,115 ordinary shares for approximately $220,000 through a pre-arranged trading plan.

Wave Life Sciences Director Adrian Rawcliffe sold 16,115 ordinary shares for a weighted-average price of $6.79 per share, pursuant to a pre-arranged trading plan.

RA Capital Management, L.P. increased its indirect beneficial ownership in Wave Life Sciences Ltd. by acquiring 1,000 ordinary shares.